Nitin Jain, MD, on CLL: Results From a Venetoclax/Ibrutinib Trial

2017 ASH Annual Meeting
Tweet this page

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results on combined venetoclax and ibrutinib for patients with previously untreated high-risk and relapsed/refractory chronic lymphocytic leukemia (Abstract 429).

Advertisement

Advertisement



Advertisement